13D Filing: Park West Asset Management and PLX Pharma Inc. (PLXP)

CUSIP No. 72942A107

 

  

Item 1.       Security
and Issuer:

The name of the issuer is PLx
Pharma Inc., a Delaware corporation (the “Issuer”).  The address of the Issuer’s principal executive
offices is 8285 El Rio Street, Suite 130, Houston, Texas, 77054.  This Schedule 13D relates to the Issuer’s common
stock, $0.001 par value per share (the “Common Stock “).

 

 

Item 2.

Identity and Background:.

	(a), (f)	This report on Schedule 13D (this “Schedule 13D”), is being jointly filed by (i) Park West Asset Management LLC (“PWAM”), a Delaware limited liability company and the investment manager to (a) Park West Investors Master Fund, Limited (“PWIMF”), a Cayman Islands exempted company and (b) Park West Partners International, Limited (“PWPI” and, collectively with PWIMF, the “PW Funds”), a Cayman Islands exempted company; (ii) PWIMF; and (iii) Peter S. Park, as the sole member and manager of PWAM (“Mr. Park” and, collectively with PWAM and PWIMF, the “Reporting Persons”).
	(b)	The principal business address for each of the Reporting Persons is c/o Park West Asset Management LLC, 900 Larkspur Landing Circle, Suite 165, Larkspur, California 94939.
	(c)	The principal business of Mr. Park is to act as the managing member of PWAM.  The principal business of PWAM is to serve as investment manager to PWIFM and PWPI.  The principal business of PWIMF is investing in securities.
	(d)	None of the Reporting Persons has, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).
	(e)	None of the Reporting Persons has, during the last five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

 

 

Item 3.	Source and Amount of Funds or Other Consideration.
	The funds used to purchase the Common Stock deemed to be beneficially owned by the Reporting Persons came from the working capital of private investment funds managed by PWAM.   The total cost of the Common Stock and warrants that the Reporting Persons may be deemed to beneficially own is $7,571,031.26.